Table 3.

Effects of pLXSN, WT-GSK-3β, and KD-GSK-3β on sensitivity of MCF-7 breast cancer cells to treatment with the GSK-3 inhibitor tideglusib in combination with drugs, signal transduction inhibitors, and a nutraceutical as determined by MTT analysis (as described previous and [49]).

Tideglusib in Combination with Drugs, Signal Transduction Inhibitor or Nutraceutical↓	+pLXSN	Fold Difference Compared to Tideglusib Alone	+WT-GSK-3β	Fold Difference Compared to Tideglusib Alone	+KD-GSK-3β	Fold Difference Compared to Tideglusib Alone
None	800 nM	-	18 nM	-	600 nM	-
0.1 nM Docetaxel	6 nM	77×↓	4 nM	4.5×↓	4 nM	150×↓
250 nM SB415286	500 nM	1.6×↓	350 nM	19.4×↑	1300 nM	2.2×↑
Metformin	100 nM	8×↓	100 nM	5.6×↑	200 nM	3×↓
Berberine	200 nM	4×↓	2000 nM	111×↑	6 nM	100×↓